Answers are grounded in this paper and cite their sources.
Candida auris osteomyelitis is an uncommon manifestation but poses a major therapeutic challenge because of limited antifungal options and management data. We report a case of a patient with multidrug resistant C. auris osteomyelitis resistant to azoles, echinocandins, and amphotericin B who was managed with aggressive surgical debridement and fosmanogepix obtained through an expanded access protocol. The patient achieved complete wound healing with clinical improvement. This case highlights the potential role of fosmanogepix as part of a multidisciplinary approach for difficult-to-treat multidrug resistant C. auris osteomyelitis and underscores the need for further clinical and pharmacokinetic studies evaluating its use in bone infections.
No takes yet. Share an insight, caveat, or question.
Alaithan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: